Evaluation of TTP399 in Patients With Type 1 Diabetes
Status:
Completed
Trial end date:
2020-01-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of TTP399 in Type 1
diabetics. This study will be in 2 phases: phase 1 will evaluate the safety of different
TTP399 dosage regimens over 1 week of daily dosing. Phase 2 will evaluate the safety and
efficacy of a TTP399 dosing regimen over 12 weeks of daily dosing.